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Cleavage and activation of hemagglutinin (HA) by trypsin-like proteases in influenza A
virus (IAV) are essential prerequisites for its successful infection and spread. In host cells,
some transmembrane serine proteases such as TMPRSS2, TMPRSS4 and HAT, along
with plasmin in the bloodstream, have been reported to cleave the HA precursor (HA0)
molecule into its active forms, HA1 and HA2. Some trypsinogens can also enhance
IAV proliferation in some cell types (e.g., rat cardiomyoblasts). However, the precise
activation mechanism for this process is unclear, because the expression level of the
physiological activator of the trypsinogens, the TMPRSS15 enterokinase, is expected
to be very low in such cells, with the exception of duodenal cells. Here, we show that
at least two variant enterokinases are expressed in various human cell lines, including
A549 lung-derived cells. The exogenous expression of these enterokinases was able
to enhance the proliferation of IAV in 293T human kidney cells, but the proliferation was
reduced by knocking down the endogenous enterokinase in A549 cells. The enterokinase
was able to enhance HA processing in the cells, which activated trypsinogen in vitro and
in the IAV-infected cells also. Therefore, we conclude that enterokinase plays a role in
IAV infection and proliferation by activating trypsinogen to process viral HA in human cell
lines.
Keywords: enterokinase, influenza A virus, hemagglutinin processing, transmembrane serine protease, genome
structure and function
INTRODUCTION
Influenza viral infections are an impending threat to humans because recent globalization has
increased the likelihood of pandemics happening with these highly infectious pathogens (Richard
and Fouchier, 2016; Saunders-Hastings and Krewski, 2016). The life cycle of influenza A virus (IAV)
begins when it adsorbs to a host cell, it enters it, becomes uncoated, proliferates, assembles into
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viral particles, and is finally released when it buds away from
the cell. The cycle is sophisticatedly regulated by many viral and
cellular factors (Medina and García-Sastre, 2011). Environmental
factors, including the host immune system, also affect viral
proliferation and infectivity (Duan and Thomas, 2016). One
such critical factor is a group of trypsin-like proteases. These
proteases activate viral hemagglutinin (HA), which is required
for viral adsorption to sialic acids on the target-cell surface and
in the uncoating process that releases viral genomic RNA into
the host cell (Fontana and Steven, 2015; Blijleven et al., 2016).
Trypsin-like proteases are located across various sites in the host’s
body. The transmembrane serine proteases (TMPRSSs), which
include TMPRSS2, TMPRSS4, and HAT, are present within cells
or on cell surfaces. In contrast, some trypsin-type proteases are
secreted in the tissues, and plasminogen occurs in the blood.
These proteases activate the precursor HA (designated HA0)
by cleavage at specific sites to generate the mature HA1 and
HA2 conformations (Goto and Kawaoka, 1998; Choi et al.,
2009; Kido, 2015). Various trypsin genes (PRSS1, PRSS2, and
PRSS3) are expressed in non-pancreatic cells in humans (Wang
et al., 2008; Yamamoto-Tanaka et al., 2014; Ghilardi et al., 2015),
and some ectopic trypsins can enhance IAV proliferation in
rat cardiomyoblasts and the lungs (Pan et al., 2011; Indalao
et al., 2017). However, the activation mechanism used by PRSS
trypsinogens is unclear, because expression of the physiological
activator enterokinase (EK, or TMPRSS15) is reported to be
restricted to duodenal epithelial cells. Because the presence of
an EK on duodenal cells activates the trypsinogens that are
secreted into the alimentary tract from the pancreas to digest food
(Kitamoto et al., 1995; Zheng et al., 2009), we hypothesized that
a small but substantial amount of EK is likely expressed in many
non-duodenal cells, where it activates trypsinogens to cleave HA0
on the influenza viruses, thereby facilitating their infection and
proliferation process.
Here, we cloned the cDNAs encoding two EK isoforms
(canonical EK and the EK-X2 isoform) from the mRNAs
present in human cells, A549 (a lung cell line) and
Huh7 (a liver cell line), respectively. A possible role
for EK in HA processing during IAV infection was
investigated via exogenous expression of EK in 293T
cells and the knocking down of endogenous EK in A549
cells.
MATERIALS AND METHODS
Cells and IAV Infection
The following cells are derived from humans. NB9
neuroblastoma cells were purchased from RIKEN BioResource
Center (http://ja.brc.riken.jp/), and maintained in RPMI 1640
medium supplemented with 15% fetal bovine serum. Capan-2
pancreatic adenocarcinoma cells were purchased from the
American Type Culture Collection (ATCC, https://www.atcc.
org/en.aspx). A549 lung adenocarcinoma cells and H292 lung
mucoepidermoid carcinoma cells were kindly provided by Dr.
Yuji Ishimatsu, Department of Cardiopulmonary Rehabilitation
Sciences, Nagasaki University Graduate School of Biomedical
Sciences, Nagasaki, Japan. HT1080 fibrosarcoma cells, HeLa
cervical epithelial carcinoma cells, Caco-2 colon adenocarcinoma
cells, TE671 rhabdomyosarcoma cells, U937 monocyte-like
histiocytic lymphoma cells 293T human embryonic kidney cells,
A431 epidermoid carcinoma cells, and Huh7 hepatocellular
carcinoma cells were obtained from already-existing collections,
and have been maintained in our laboratory for a long time.
They were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum, except
for the U937 cells, which were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum. MDCK canine
kidney cells were purchased from Dainippon Pharmaceutical
Co., Ltd, Osaka, Japan, and cultured in Eagle’s minimal essential
medium (E-MEM) supplemented with 10% fetal bovine
serum.
We used the influenza A/WSN/1933(H1N1) strain in most
experiments, except the experiment shown in Figure 8, in which
the influenza A/Aichi/2/68 (H3N2) strain was used. Human
cells (1 × 105 of each) were plated in a 24-well plate and
inoculated with different amounts of the WSN strain of IAV
(multiplicity of infection [MOI] = 0.001–0.1, diluted with 0.1%
bovine serum albumin [BSA] in medium) at 37◦C for the
indicated periods. After the removal of the supernatant, the
cells were lysed with 100 µl of GLB lysis buffer (Promega
Corporation, Madison, WI, USA). The lysates were cleared
by centrifugation at 20,000 × g for 2min at 4◦C, combined
with a 1/3 volume of 4 × SDS-PAGE sample buffer, separated
electrophoretically, and subjected to western blotting. For the
experiment shown in Figure 8, 293T cells and 293T cells
expressing EK-X2 (clone #7-6) in a 24-well plate were inoculated
with the influenza A/Aichi/2/68 (H3N2) strain (MOI = 0.1),
which was allowed to adsorb for 1 h at 34◦C. The inoculum
was removed and replaced with DMEM containing 0.1% BSA
with or without 5µg/ml trypsin. After incubation for 48 h at
37◦C, the supernatant was collected and analyzed with a plaque
assay. Briefly, MDCK cells were inoculated with serial 10-fold
dilutions of the samples, overlain with 2% agar containing
5µg/ml trypsin, and incubated at 37◦C for 48 h. The agar
was removed and the cells were stained with 0.1% crystal
violet.
Focus Forming Assays
Focus forming assays were performed according to the
method described previously (Matrosovich et al., 2006). In
short, MDCK cells (3 × 104 of each) were seeded onto a
96-well plate and inoculated with five-fold serial dilutions
of supernatant (collected from infected cells) in E-MEM
containing 0.1% BSA at 35◦C and allowed to adsorb. After
1 h of incubation, an equal volume of 1.2% Avicel (colloidal
cellulose, Sigma-Aldrich #435244,) containing E-MEM, 10%
fetal bovine serum, and 90µg/ml N-tosyl-L-phenylalanyl
chloromethyl ketone (TPCK)-treated trypsin (Worthington
Biomedical Co.) was added to the wells. The plate was mixed
by tapping, and incubated at 37◦C for 24 h. The plated cells
were fixed with 3.7% formaldehyde and immuno-stained
with an anti-IAV nucleoprotein antibody (Sino Biological
Inc.) and TrueBlue peroxidase substrate (KPL) to count the
foci.
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cDNA Cloning and Reverse Transcription
(RT)–PCR
Total mRNAs were extracted from the human cells with
the standard acid guanidinium thiocyanate–phenol–chloroform
method, and the cDNAs were synthesized with an oligo(dT)18
primer and ProtoScript II Reverse Transcriptase (New England
Biolabs Inc., Ipswich, MA USA). The primers used to amplify
the different genes from the cDNAs are listed in Table 1.
For the PCR, the same amounts of total RNAs were used,
and amplified in 45 cycles (denaturation for 10 s at 98◦C,
annealing for 10 s at 60◦C, and extension for 30 s at 70◦C) with
KOD-FX DNA Polymerase (Toyobo Co., Ltd, Osaka Japan) on
an Applied Biosystems LightCycler 1.5 thermocycler (Thermo
Fisher Scientific Inc., Waltham, MA USA), unless otherwise
stated.
To clone the full-length EK cDNA, we amplified the
overlapping N-terminal and C-terminal halves of the cDNA
separately, using the cDNAs from A549 cells and Huh7 cells
as the templates and the specific primers listed in Table 2,
and then combined them at the unique PpuMI restriction site.
To introduce a mutation at the conserved triad H–D–S (Choi
et al., 2009), we used the PrimeSTAR Mutagenesis Basal Kit
(Takara Bio Inc., Kusatsu, Japan). The sequence was changed
from TCAGGAGGACCA (Ser971GlyGlyPro in canonical EK)
to GCAGGAGGGCCC (Ala971GlyGlyPro in the EK mutant),
introducing an ApaI restriction site that did not affect the coding
amino acid sequence, to distinguish the mutant from the wild
type easily with ApaI digestion. To change the wild-type Ser1001
of EK-X2 to the mutant Ala1001, the wild-type C-terminal half
of EK-X2 was replaced with the mutant C-terminal half of EK
at the unique PpuMI site. All constructs generated with PCR
were confirmed with DNA sequencing. Other cDNAs, encoding
TMPRSS2, TMPRSS4, HAT, PRSS1, PRSS2, and PRSS3, were also
cloned with RT–PCR from the total RNA from the human cells
listed above, using the specific primers listed in Table 2. All the
constructs were confirmed with DNA sequencing.
TABLE 1 | Primer sequences used for RT-PCR.
Genes Forward Reverse
Enterokinase
For all variants GCACCTGATGGCCACTTAAT CCAGTCACTGCTGACGAGAG














famplified in 40 cycles.
TABLE 2 | Primer sequences used for cloning cDNAs.
Region Forward Reverse
Enterokinase
N-terminal halfa ATGGGGTCGAAAAGAGGCATATCTTCTAGG CTCAAAAGGTCCTCCACAGTCCGTAGG







The cDNAs were amplified in 45 cycles (10 s denaturation at 98◦C, 10 s annealing at 60◦C, and 2min extension at 70◦C) except for
aannealing temperature: 65◦C.
bannealing temperature: 58◦C.
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Establishment of Stable Cell Lines
To establish stable 293T clones expressing EK or EK-X2, we
transfected the cells with a pcDNA vector (Thermo Fisher)
expressing the EK or EK-X2 cDNA together with a hygromycin-
resistance gene. After selection with 150µg/ml hygromycin B
(Thermo Fisher), several independent clones expressing EK or
EK-X2 were isolated and analyzed.
To establish stable A549 cells, we used a lentiviral vector
(the pLVX series, TaKaRa) to express small hairpin RNAs
(shRNAs) under the control of the U6 promoter (the target
sequences knocked down are listed in Table 3), together with a
puromycin-resistance gene or blasticidin-resistance gene under
the control of the PGK promoter. The recombinant lentiviruses
were constructed by simultaneously transfecting 293T cells with





the pLVX vector and lentiviral plasmids expressing Gag/Pol, Rev,
and VSVG (Naldini et al., 1996). After selection with 1.3µg/ml
puromycin (Nacalai Tesque, Inc., Kyoto, Japan), the puromycin-
resistant A549 cells expressing RIG-I-targeting shRNA were
pooled, and stored for analysis and subsequent experiments.
The sh-RIG-I A549 cells were then infected with recombinant
lentiviruses expressing shRNAs targeting different sites in the EK
mRNA (sh-EK#1, sh-EK#2, and control shRNA), and selected
with 180µg/ml blasticidin S (Wako Pure Chemical Industries,
Ltd, Osaka, Japan). The blasticidin-resistant cells were pooled and
analyzed.
IAV Processing in Vitro
We obtained IAV-HA0-rich lysates fromU937 lymphoma cells (2
× 105 cells in a 24-well plate) infected with IAV (MOI = 0.1) for
48 h, because IAV proliferates better in lymphoma cells than in
293T cells without HA0 processing for 48 h. To lyse the cells in
the 24-well plate, we used 100 µl of GLB lysis buffer (Promega)
per well. The IAV-HA0-rich lysates were incubated with N-tosyl-
L-phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (0,
3, or 9µg/ml) or lysate including either EK or EK-X2 for 30min
at room temperature. The reaction was terminated by adding
a 1/3 volume of 4 × SDS-PAGE sample buffer. The samples
FIGURE 1 | Expressions of HA after infection of IAV [A/WSN/1933(H1N1)] in various human cell lines. Human cell lines (1 × 105 cells) of various origins (HT1080,
fibrosarcoma; HeLa, cervical epithelial carcinoma; A549, lung adenocarcinoma; Caco-2, colon adenocarcinoma; TE671, rhabdomyosarcoma; U937, monocyte-like
histiocytic lymphoma; H292, lung mucoepidermoid carcinoma; 293T, human embryonic kidney; A431, epidermoid carcinoma; Capan-2, pancreatic adenocarcinoma;
Huh7, hepatocellular carcinoma; and NB9, neuroblastoma) were plated in a 24-well plate and inoculated with IAV [A/WSN/1933(H1N1)] (MOI = 0.1). The cell lysates
were prepared 48 h after IAV infection, separated electrophoretically, and subjected to western blotting with a specific antibody directed against IAV HA to estimate the
amount of viral proliferation in the cells. The 65-kDa precursor IAV HA0 protein is indicated with arrow.
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were subjected to electrophoresis and western blotting with an
anti-HA antibody.
Trypsin Activity Assay
Trypsin activity was monitored as the amount of p-
nitroaniline (pNA) released from a specific substrate, measured
spectrophotometrically at 405 nm (Colorimetric Trypsin Activity
Assay Kit, BioVision, Inc., Milpitas, CA, USA; Hayashi et al.,
2011). The substrate and 293T cell lysates exogenously expressing
trypsinogen (PRSS1, PRSS2, or PRSS3) were incubated with the
293T cell lysates exogenously expressing various transmembrane
serine proteases (TMPRSS2, TMPRSS4, HAT, or EKs) at room
temperature for the indicated periods. The amount of released
pNA from the substrate by trypsinogen (PRSS1, PRSS2, or
PRSS3) activated with the indicated transmembrane serine
proteases was measured as the trypsinogen-activating function.
Western Blotting
Cell lysates were separated with 10% SDS-PAGE (Bio-Rad
Laboratories, Inc. Hercules, CA, USA) and transferred to
polyvinylidene difluoride membranes (Merck Millipore
Corporation, Darmstadt, Germany). To detect the specific
proteins, an anti-HA antibody (Sino Biological Inc., Beijing,
China #11684-RP01), anti-EK antibody (Sigma-Aldrich Co.
LLC, St. Louis, MO, USA #HPA015611), anti-PRSS3 antibody
(ABGENT San Diego, CA, USA #AP11927c), or anti-RIG-I
antibody (Ana Spec Inc., Fremont, CA, USA #54285) was used
at a dilution of 1:500–1:2,000. The proteins were visualized
with horseradish-peroxide-conjugated anti-rabbit IgG antibody
(Bio-Rad), and enhanced chemiluminescent reagent (Bio-Rad).
Statistical Analysis
Quantitative data were analyzed using Student’s t-test with a
2-tailed p-value. The n for each analysis is represented in the
Figure legends. A value of p < 0.05 was considered statistically
significant.
RESULTS
Expression of TMPRSSs and PRSSs
We first examined HA expression 48 h after initiating IAV
infections [A/WSN/1933(H1N1)] in various human cell lines
(Figure 1). High levels of HA0 protein were detected in the IAV-
inoculated Caco-2, TE671, U937, 293T, Huh7, and NB9 cells,
suggesting that IAV replicates efficiently in these cells. Low levels
of HA0 protein were detected in HT1080- and A549-inoculated
cells, but almost no HA0 protein was detected in HeLa, H292,
A431, or Capan-2 cells. To evaluate the factors involved in
HA processing, we further examined the expression profiles of
transmembrane serine proteases (TMPRSSs) and trypsinogens
FIGURE 2 | Expression of transmembrane serine proteases and trypsinogens. Total mRNAs from several human cell lines (293T, embryonic kidney; Huh7, hepatoma;
A431, epidermoid carcinoma; HT1080, fibrosarcoma; H292, lung carcinoma; and A549, lung carcinoma) shown in Figure 1 were prepared, and their cDNAs were
synthesized from the same amounts of total RNA with an oligo(dT)18 primer. The transcript copies of the TMPRSS genes (A) and trypsinogen genes (B) were
amplified by 45 cycles of PCR with primers specific for each gene, separated electrophoretically and stained. Posi.: 1 × 104 molecules of target cDNA was used as
each positive control. Nega.: H2O.
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FIGURE 3 | Schematic structure of the EK gene. The 5′-region of EK gene is shown as an open box, containing exons 3–6 of the total 25 exons of canonical EK
(TMPRSS15; accession number NM_002772.2), and the additional exons of isoforms X1–X4 (XM_011529654.1–011529659.1), deduced from the GenBank data, are
shown as solid black boxes. The three transcript variants (XM_011529654.1–011529656.1) encode the same isoform X1 with different 5′ untranslated regions. The
boxed X2 isoform (XM_011529657.1) was actually cloned from Huh7 liver cells, and contains an additional 90-bp exon between exons 3 and 4 of canonical EK.
FIGURE 4 | Schematic structures of EK and EK-X2, and their expression in various human cells. (A) Exons 2–6 of canonical EK (NM_002772.2) and the additional
exon of the EK-X2 isoform (XM_011529657.1) are shown, as in Figure 3. Thick arrows indicate the primer sites in exon 2 and exon 6 of EK used for RT–PCR. (B)
RT–PCR products after 45 cycles of cDNA amplification (293T, embryonic kidney; Huh7, hepatoma; A431, epidermoid carcinoma; HT1080, fibrosarcoma; H292, lung
carcinoma; A549, lung carcinoma), using the primers shown in (A), were separated electrophoretically on a 6% acrylamide gel and stained. Arrows indicate the PCR
products of EK (491 bp) and EK-X2 (581 bp). Posi.: 1 × 104 molecules of canonical EK cDNA were used as each positive control. Nega.: H2O. (C) In the EK-X2
isoform, an additional 90-bp exon is inserted immediately before the autoproteolysis motif (GSIIV) in the SEA domain of canonical EK.
in the cells, using RT–PCR and specific primers (Figure 2).
EK was ubiquitously expressed in all the cells we examined,
whereas TMPRSS4, TMPRSS2, and HAT were expressed in
only some of them (Figure 2A). The lung-derived A549 cells
expressed EK, but not TMPRSS4, TMPRSS2, and HAT. In
contrast, the other lung-derived H292 and HT1080 fibrosarcoma
cells expressed substantial level of TMPRSS4, TMPRSS2, and
HAT as well as EK. Considering the HA expression patterns
in Figure 1 (e.g., high in 293T and Huh7, low in HT1080
and A549, and almost non-existent in H292 and A431), the
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FIGURE 5 | Enhanced proliferation of IAV in 293T cells exogenously expressing EK. (A) Two independent 293T clones, stably expressing EK or EK-X2, were isolated
by drug selection, as described in section Materials and Methods. The same cell lysate amounts were electrophoresed and then western blotted with an anti-EK
antibody. The major EK protein band (170 kDa) and the slightly larger EK-X2 band are indicated by arrows, and the band intensities are shown below. (B) 293T cells (1
× 105) in a 24-well plate were inoculated with different amounts of IAV (MOI = 0, 0.001, or 0.01 from the left of ). At 48 h post-infection, the same cell lysate
amounts were electrophoresed and western blotted with an anti-IAV HA antibody. The 65-kDa precursor IAV HA0 and the cleaved 25-kDa C-terminal IAV HA2
fragment are indicated by arrows. The HA0 and HA2 intensities and the HA2/HA0 ratio are shown below. (C) 293T cells (1 × 10
5) in a 24-well plate were inoculated
with IAV (MOI = 0.001). At 48 h post-infection, the viral spread was quantified as the release of infectious particles into the culture supernatants, as measured by a
focus forming assay in MDCK cells. Data represent mean ± standard deviation of three experiments, *significantly different at p < 0.05.
TMPRSS expression profile was clearly not directly related to
HA expression. As for the trypsinogen genes (PRSS1, PRSS2,
and PRSS3 in human cells), PRSS1 and PRSS3 were expressed
ubiquitously, but the expression profile of PRSS2 was low in
A549, H292, and HT1080 cells (Figure 2B). Taken together, it is
clear that each cell line expressed some TMPRSSs and PRSSs that
are capable of processing HA0 to the active form, although the
specific molecules responsible for HA expression and processing
were not identified.
To clarify the role of EK in IAV infection, we cloned the
full-length EK cDNAs. The 5′ region of the EK gene is shown
in Figure 3. In addition to the canonical EK (TMPRSS15:
accession number NM_002772.2), four isoforms (X1–X4) with
six transcript variants (accession numbers XM_011529654.1–
011529659.1) of EK were predicted using an automated
computational analysis of the genomic sequence available in
the NCBI GenBank database (https://www.ncbi.nlm.nih.gov/
genbank/). The three transcript variants (XM_011529654.1–
011529656.1) each encode the same protein isoform (X1) but
with different 5′ noncoding regions, and the differences in
the coding regions of the X1–X4 isoforms arise from splicing
differences between exon 3 and exon 6, including an additional
two exons in the canonical EK. We cloned the full-length cDNA
encoding the canonical EK from A549 lung-derived cell mRNA
(NM_002772.2), and the full-length X2 isoform cDNA from
Huh7 liver-derived cells (XM_011529657.1; boxed in Figure 3).
Thus, we have designated the canonical cDNA as “EK” and
the X2 isoform as “EK-X2.” To further examine the expression
profiles of these EK variants in human cell lines, we synthesized
specific primers that anneal to exons 2 and 6 of the canonical
EK (Figure 4). The expected lengths of the PCR products from
EK and EK-X2 were 491 and 581 bp, respectively. The size
difference is caused by the insertion of an additional 90-bp exon
immediately before the autoproteolysis motif in the SEA (sea
urchin sperm protein, enterokinase, and agrin) domain of EK
(Figure 4C). Canonical EK was endogenously expressed in A549,
H292, HT1080, and A431 cells, whereas the EK-X2 isoform was
endogenously expressed in A431, Huh7, and 293T cells. Judging
from the extra bands, HT1080 cells may express other isoforms
in addition to canonical EK (Figures 3, 4B). These data indicate
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that canonical EK and its isoforms (at least the X2 isoform) are
expressed in many cells other than duodenal cells.
Exogenous Expression of EK or EK-X2
Enhances IAV Proliferation
To examine the effects of the EKs on IAV infection, we expressed
EK or EK-X2 exogenously in 293T cells (Figure 5A). We
analyzed two independent, stable clones for each construct to
avoid clonal deviation. The major EK protein band (170 kDa),
and a slightly larger EK-X2 protein band, were detected in the
transfected cells using a specific anti-EK antibody. To assess
the extent of HA processing quantitatively, we measured the
intensities of HA0 and HA2, and the HA0/HA2 ratio (Figure 5B).
Although the amounts of the 65-kDa HA0 precursor and the
25-kDa cleaved C-terminal HA2 fragment showed increases, the
25-kDa HA2 fragment showed a much more stronger increase
(thereby elevating the HA0/HA2 ratio) after EK or EK-X2
were exogenously expression compared with the 65-kDa HA0
precursor, indicating that EK and EK-X2 enhanced not only
IAV proliferation, but also HA processing. The EK-mediated
proliferation of infective IAV was confirmed by the significant
increase of virus release into the media (Figure 5C). We also
analyzed the function of EK in activating the PRSS3 trypsinogen
in vitro (Figure 6). A lysate of 293T cells exogenously expressing
a large amount of PRSS3 (Figure 6A) was used as the source of
trypsinogen. Although 293T cells endogenously express certain
levels of PRSS1 and PRSS3, the lysate exogenously expressing
PRSS3 alone (PRSS3 trypsinogen lysate) showed no catalytic
activity for a pNA-attached trypsin substrate. Consequently, the
authenticity of the substrate was confirmed by the observation
that free pNA was markedly released when the PRSS3 lysate was
incubated with a purified EK (GenScript, #Z01003). Each 293T
cell lysate exogenously expressing EK, TMPRSS2, TMPRSS4,
HAT proteases, or vector alone, was mixed with the PRSS3 lysate
FIGURE 6 | Activation of trypsinogen PRSS3 by TMPRSSs. The activation of trypsinogen PRSS3 by TMPRSSs was measured in vitro by incubating
PRSS3-expressing cell lysates with a specific substrate and cell lysates expressing the indicated TMPRSSs. (A) 293T cells transfected with a PRSS3-expressing
plasmid or vector alone were lysed at 48 h post-transfection, electrophoresed, and then western blotted with an anti-PRSS3 antibody. The 26-kDa PRSS3 band is
indicated with arrow. (B) The PRSS3-expressing 293T cell lysate was mixed with 293T cell lysate transiently expressing one of the indicated TMPRSS proteases (EK,
TMPRSS2, TMPRSS4, HAT, or vector only) for the indicated periods. The amount of pNA released from the specific substrate in the mixture was measured at 405 nm
as the trypsinogen-activating function (trypsin activity). (C) Lysates prepared from 293T cells stably expressing EK (clone #5-1), EK-X2 (clone #7-6), or vector alone
(293T-cont.), shown in Figure 5, were incubated with PRSS3-epressing 293T cell lysate, and the trypsinogen-activating function was measured. (D,E) 293T cell
lysates expressing EK (D) or EK-X2 (E) were mixed with 293T cell lysates transiently expressing one of the indicated trypsinogens (PRSS1, PRSS2, PRSS3, or vector
only) for the indicated periods. The amount of pNA released from the specific substrate in the mixture was measured at 405 nm as the trypsinogen-activating function
(trypsin activity).
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and the specific trypsin substrate to measure PRSS3 activation
by the transmembrane proteases (Figure 6B). The EK lysate was
able to activate PRSS3 in a time-dependent manner. In contrast,
TMPRSS2, TMPRSS4, and HAT were all unable to activate
PRSS3, which indicates that only EK can cleave and activate the
PRSS3 trypsinogen. A trypsinogen-activating function was also
detected in the 293T cell lysates stably expressing EK or EK-
X2 (Figure 6C). EK- and EK-X2-mediated activation of PRSS1
and PRSS2 produced marginal results, unlike that with PRSS3
(Figures 6D,E). These findings indicate that PRSS3 is a major
activator of EK and EK-X2 in vitro.
The His825-Asp876-Ser971 residues in canonical EK form the
evolutionarily-conserved H–D–S catalytic triad present in many
serine proteases (Choi et al., 2009). We constructed protease-
deficient mutants by replacing Ser971 of EK and Ser1001 of EK-X2
with Ala. Upon electrophoresis, the mutant proteins were a little
smaller than the wild-type proteins (Figure 7A). Although the
expression levels of the mutant proteins were more than halve of
those of the parental proteins in 293T cells, neither of the mutant
EKs displayed enzymatic activity (Figure 7B) or any enhancing
effect on HA processing or IAV proliferation (Figure 7C) in the
293T cells compared with those of the control. This indicates that
the enhancing effects of EK and EK-X2 on IAV infection depend
on their PRSS3-activating functions.
Because the trypsin requirement differs among viral strains,
we investigated the effects of EK expression on infection with
another IAV strain [A/Aichi/2/68 (H3N2)]. The A/Aichi/2/68
(H3N2) strain requires more trypsin to enhance its proliferation
in host cells than the A/WSN/1933(H1N1) strain (Goto and
Kawaoka, 1998). The level of IAV proliferation 48 h after
infection at a multiplicity of infection (MOI) of 0.1, as measured
by a plaque assay in MDCK cells, was significantly higher
in the EK-X2-expressing 293T cells (clone #7-6) than in the
293T cells (Figure 8). Treatment of the IAV strain with trypsin
significantly enhanced viral proliferation over 48 h in both 293T
and EK-X2-expressing 293T cells (#7-6). The marked increase
FIGURE 7 | Protease-deficient mutant EK or EK-X2 has almost no effect on IAV infection. (A) The protease-deficient mutants in which Ala replaced EK Ser971 or
EK-X2 Ser1001 in the catalytic triad (H–D–S), as well as wild type EK and EK-X2, were transiently expressed in 293T cells, and the cell lysates were analyzed with
western blotting using an anti-EK antibody. The two major protein bands of EK (170 and 140 kDa) and the EK mutant and the slightly larger bands of EK-X2 and its
mutant are indicated with arrows, and the band intensities are shown below. (B) The 293T cell lysates transiently expressing wild type EK, EK-X2, or the
protease-deficient mutants were mixed with the PRSS3-expressing 293T cell lysate. The amounts of pNA released from the substrate were measured at 405 nm as
the trypsinogen-activating function. (C) 293T and mutant EK- or EK-X2-expressing cells (1 × 105 each) were plated in a 24-well plate and inoculated with different
amounts of IAV (MOI = 0, 0.001, 0.01 from the left of ). At 48 h after infection, the same amounts of cell lysates were subjected to electrophoresis and western
blotting with an anti-IAV HA antibody. The 65-kDa precursor IAV HA0 and the cleaved 25-kDa C-terminal IAV HA2 fragment are indicated by arrows. The HA0 and
HA2 intensities and the HA2/HA0 ratio are shown below.
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FIGURE 8 | Effects of EK-X2 on infection by another IAV strain, A/Aichi/2/68
(H3N2). The effects of EK-X2 expression on infection by another IAV strain,
A/Aichi/2/68 (H3N2), were examined. Levels of IAV proliferation in 239T and
EK-X2-expressing 293T cells (#7-6) 48 h after infection with the virus (MOI =
0.1), with or without 5µg/ml trypsin, were measured with a plaque assay in
MDCK cells. Data represent mean ± standard deviation of three experiments.
*Significantly different (p < 0.05).
in IAV proliferation in the 293T cells without trypsin treatment
indicates that EK-X2 expression in these cells was able to enhance
the proliferative ability of the Aichi strain (in addition to the
WSN strain), although the additional enhancing effect of trypsin
treatment in the EK-X2-expressing cells suggests that the EK-
X2-dependent viral proliferation in the cells was partial and
incomplete.
EK and EK-X2 Trigger HA Processing by
Activating the PRSS3 Trypsinogen
We next examined the effects of the EKs on HA processing,
when inactive HA0 is converted to the HA1 and HA2 active
forms via cleavage at a specific arginine residue, both in vitro
and in the infected cells. To access the effect of the exogenously
expressed EKs on HA processing, we first analyzed the dynamics
of the HA molecules after the 293T cells were infected with
different amounts of IAV (MOI = 0.001, 0.01). Cell proteins
were western blotted with an anti-HA antibody that detects
the 65-kDa HA0 and the C-terminal 25-kDa HA2 fragment
(Figure 9A). The 65-kDa HA0 protein was detected in the
cell lysates 12 h after IAV infection (MOI = 0.01), and the
processed 25-kDa HA2 fragment was observed 72 h after the
cells were infected with IAV. HA processing proceeded in
a time- and dose-dependent manner in the 293T cells, and
was enhanced by the presence of EK and EK-X2 alike, as
has already been shown in Figure 5. We next examined HA
processing in vitro, by preparing IAV from U937 lymphoma
cells because the amount of IAV-HA0 was higher than in the
293T cells where marginal HA0 processing occurs, even at 48 h
post-infection (Figure 1). The IAV-HA0-rich cell lysates were
incubated with TPCK-treated trypsin or lysates containing EK
(Figure 9B). The trypsinogen PRSS3, EK, or EK-X2 alone had
no effect on HA0, but HA0 disappeared and HA2 appeared
correspondingly after treating PRSS3 with EK or EK-X2, as
also occurred after treatment with TPCK-treated trypsin. This
indicates that both EK and EK-X2 cleaved and activated
trypsinogen to process HA0 into HA1 and HA2 in vitro and in
the cells.
Endogenous EK in A549 Lung-Derived
Cells Plays a Role in IAV Infection
To evaluate the role of endogenous EK in IAV infections, we
used A549 lung-derived cells because the lungs are a primary
target of IAV, and because these cells express a certain level of EK,
but do not express TMPRSS2, TMPRSS4, or HAT (Figure 2A).
However, the HA expression level was relatively low in the A549
cells, compared with the 293T and Huh7 cells. Therefore, to
clarify the effects of the EK knockdown, we first established
an A549 cell line that permitted good proliferation IAV by
knocking down the critical signaling molecules that trigger
interferon production by sensing IAV infection. Among these
signaling molecules (data not shown), the RIG-I knockdown
was the most effective at enhancing IAV proliferation and HA
expression.
Thus, to establish A549 cells capable of stably expressing
shRNA directed against RIG-I (A549–sh-RIG-I), we infected
A549 cells with a recombinant lentivirus expressing the verified
sh-RIG-I and a puromycin-resistance gene. The drug-resistant
cells were pooled to avoid clonal deviation while establishing
the stable cell lines. We noted that the RIG-I protein levels
reduced significantly when shRNA was expressed in the cells
(Figure 10A). Although HA processing was not observed clearly,
the amount of HA0 and the release of infective viruses into the
culture media were enhanced in the A549 cells by knocking down
the endogenous RIG-I with shRNA (Figures 10B,C). We further
synthesized two shRNAs (sh-EK#1 and sh-EK#2) targeting
different sites in the EK mRNA to knockdown endogenous
EK in the A549 cells with a recombinant lentivirus vector. To
avoid clonal deviation in the stable cell lines we established,
we pooled the drug-resistant cells expressing the verified EK-
directed shRNAs in the A549–sh-RIG-I cells. The sh-EK#2–
mediated EK knockdown was more effective at reducing the
amount of HA0 and the spread of infective virus than that
of shEK#1 (Figure 11). These results indicate that endogenous
EK plays a role in enhancing IAV proliferation in A549
cells.
DISCUSSION
We have shown that at least two EK isoforms are expressed
in human cell lines, including in A549 lung-derived cells. The
enhancing effects of exogenously expressed canonical EK or EK-
X2 on IAV infection depended on their protease activities, and
correlated with HA processing and trypsinogen activation. In
addition to the HA-processing pathway via the other TMPRSSs
reported to date, we propose a novel pathway that enhances
IAV infection via EK, which activates trypsinogen to process the
HA0 precursor into mature HA1 and HA2 fragments, as shown
schematically in Figure 12.
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FIGURE 9 | Processing IAV HA. (A) 293T cells (1 × 105) plated in a 24-well plate were inoculated with IAV (MOI = 0.001, 0.01). Cell lysates were prepared after the
indicated periods and subjected to electrophoresis and western blotting with an anti-IAV HA antibody. (B) IAV HA0 was prepared from IAV-infected U937 lymphoma
cells (MOI = 0.1), which permit IAV proliferation, and was used in processing experiments in vitro. IAV HA0 lysates were incubated for 30min at room temperature with
TPCK-treated trypsin (0, 3, or 9µg/ml) or with the indicated lysates expressing PRSS3, EK, EK-X2, or vector only (–), and then subjected to western blotting with an
anti-IAV HA antibody. The 65-kDa precursor IAV HA0 and the cleaved 25-kDa C-terminal IAV HA2 fragment are indicated by arrows. The HA0 and HA2 intensities and
the HA2/HA0 ratio are shown below.
As shown in Figure 2, lung-derived A549 cells predominantly
express EK among the TMPRSSs. This is one explanation for why
knocking down endogenous EK in A549 cells resulted in reduced
IAV proliferation (Figure 11). In contrast, the EK knockdown
in 293T cells had almost no effect on IAV proliferation (data
not shown). This is understandable because 293T cells express
both TMPRSS2 and EK, and TMPRSS2 can activate HA even in
the absence of EK. Among the TMPRSSs, TMPRSS2 (Böttcher
et al., 2006; Chaipan et al., 2009; Bertram et al., 2010; Hatesuer
et al., 2013; Sakai et al., 2014; Kühn et al., 2016), TMPRSS4
(Chaipan et al., 2009; Bertram et al., 2010; Kühn et al., 2016),
HAT (TMPRSS11D) (Böttcher et al., 2006), matriptase (ST14)
(Hamilton et al., 2012), DESC1 (TMPRSS11E) (Zmora et al.,
2014), and TMPRSS13 (MSPL) (Okumura et al., 2010; Zmora
et al., 2014) have all been reported to cleave and activate IAV
HA. Additionally, TMPRSS2 has been shown to be a major
target of many IAV strains including H1N1 in vivo by using
knockout mice (Kim et al., 2006; Hatesuer et al., 2013; Sakai
et al., 2014), whereas, TMPRSS4 was a target of another IAV
strain (H3N1) in vivo (Kühn et al., 2016). As for the WSN strain,
it uses plasmin to cleave HA0 with the help of neuraminidase
(NA) (Goto and Kawaoka, 1998). These findings show that host
proteases play an important role in determining the cell or tissue
tropism of an IAV strain. However, the host protease that is
used by IAV depends not only on the expression profiles of
the relevant proteases in the targeted cell, but other factors that
also regulate protease functions, such as EK-related activation
of PRSS3. IAV itself affects the selection process by inducing
various cytokines such as interferons, tumor necrosis factor α,
and interleukin 1β (IL-1β), or by inhibiting various cellular
responses in order to replicate in the cell. For example, IAV-
induced IL-1β stimulates the expression of PRSSs, including
PRSS3, in several cell types (Indalao et al., 2017), and elevated
PRSS3 protein is activated by EKs to induce HA processing.
Therefore, EKs may play a role in IAV pathogenicity and cell
tropism via PRSS3.
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FIGURE 10 | Knockdown of RIG-I enhanced IAV proliferation in A549 cells. (A) A549 cells stably expressing the control shRNA (sh-cont.) or the shRNA confirmed as
targeting RIG-I mRNA (sh-RIG-I) were generated by infection with an shRNA-expressing recombinant lentivirus and drug selection, as described in the section
Materials and Methods. To verify the shRNA targeting RIG-I, the cell lysates were subjected to western blotting with an anti-RIG-I antibody. The 110-kDa RIG-I band is
indicated with an arrow, and the band intensity is shown below. (B) A549 cells were infected with IAV (MOI = 0, 0.001, 0.01, 0.1 from the left of ) for 48 h, and the
proliferation of IAV was analyzed with western blotting using an anti-HA antibody. The 65-kDa precursor IAV HA0 is indicated with arrows. Intensities of HA0 and HA2,
and the HA2/HA0 ratio were shown below. (C) The indicated A549 cells (1 × 10
5) in a 24-well plate were inoculated with IAV (MOI = 0.001). At 48 h post-infection,
the viral spread was quantified as the release of infectious particles into the culture supernatants, as measured by a focus forming assay in MDCK cells. Data
represent mean ± standard deviation of three experiments, *Significantly different at p < 0.05.
To effectively prevent or cure IAV infection, therapeutic
interventions targeting several molecules simultaneously are
worth considering. Developing inhibitors against trypsin-like
proteases, such as TMPRSS2 and EK, is warranted because
targeting viral proteins, including HA and NA, could stimulate
the emergence of resistant mutant viruses, given the highly
variable nature of IAV. The characteristic structure of EK, whose
catalytic domains are exposed on the cell surface, facilitates the
development of inhibitors that have minimal adverse effects.
The strict substrate specificity of EK for the DDDDK amino
acid sequence makes it particularly suitable for circumventing
possible adverse effects. The combined use of EK inhibitors with
other reagents may exert the maximal damaging effect on IAV
during its infection.
Although no functional differences between EK and EK-
X2 were apparent in this study, the insertion of an additional
90-bp exon (encoding 30 amino acids) just before the GSIIV
autoproteolysis motif might modify the structure and function
of the 118 amino acids of the SEA domain in canonical EK
(Figure 4C). As its name implies, the canonical SEA domain was
first detected in sea urchin sperm protein, and in EK and agrin
proteins also, but its function is not well understood, except that
it is known to be involved in the autoproteolysis that causes
subsequent functional domains to be shed or the protein to be
degraded, and it also has an effect on the carbohydrate chains
nearby it (List et al., 2006). Recent advanced search programs
have shown that many molecules contain the SEA domain,
including some mucins, glycans, phosphatases, and cadherins
(Pei and Grishin, 2017). Because the 90-bp exon of EK-X2 is
inserted immediately before the autoproteolysis motif in EK, it
may affect some EK functions as yet unknown or contribute a
new function for the SEA domain. It is intriguing that many cell
lines express canonical EK, but some express EK-X2, and possibly
other variants (Figure 4B). The Human Protein Atlas project
provides information on the overall expression levels of EK
without differentiating its variants (The Human Protein Atlas,
2017). EK expression at the RNA level in A549 cells is marginal,
compared with that in the brain cancer cell lines U-87MG andU-
138MG. The very high expression level of EK in brain cell lines
requires further examination because EK might be involved in
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FIGURE 11 | Knockdown of endogenous EK in the A549 cells expressing sh-RIG-I reduced IAV proliferation. (A) sh-RIG-I-expressing A549 cells also expressing
shRNAs targeting different sites in EK (sh-EK#1, sh-EK#2, or sh-cont.) were generated by infecting the cells with a recombinant lentivirus expressing an shRNA and a
blasticidin-resistant gene. The drug-resistant cells were pooled and infected with IAV (MOI = 0, 0.001, 0.01, 0.1 from the left of ). At 48 h post-infection, the same
cell lysate amounts were electrophoresed and western blotted with an anti-IAV HA antibody. The 65-kDa precursor IAV HA0 and the cleaved 25-kDa C-terminal IAV
HA2 fragment are indicated by arrows. The HA0 and HA2 intensities and the HA2/HA0 ratio are shown below. (B) A549 cells (1 × 10
5) in a 24-well plate were
inoculated with IAV (MOI = 0.001). At 48 h post-infection, the viral spread was quantified as the release of infectious particles into the culture supernatants, as
measured by a focus forming assay in MDCK cells. Data represent mean ± standard deviation of three experiments. *Significantly different at p < 0.05.
FIGURE 12 | Schematic representation of HA processing by EK and
trypsinogen. The novel pathway that enhances IAV infection via EK is shown
with solid arrows. EK activates trypsinogen PRSSs to process the precursor
HA0 into the active HA1 and HA2 conformations. The known transmembrane
serine protease (TMPRSS) pathway, involving TMPRSS2, TMPRSS4, and HAT,
which directly activates HA processing, is shown with open arrows.
IAV-induced encephalopathy or abnormal psychiatric behaviors.
The physiological roles of EK, especially in the lung and brain,
after IAV infection in vivo deserve future research.
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